Vectura Group PLC (VEC.L)
VEC.L on London Stock Exchange
85.25GBp
18 May 2018
85.25GBp
18 May 2018
Change (% chg)
-1.45 (-1.67%)
-1.45 (-1.67%)
Prev Close
86.70
86.70
Open
86.60
86.60
Day's High
87.50
87.50
Day's Low
83.70
83.70
Volume
2,791,327
2,791,327
Avg. Vol
6,154,256
6,154,256
52-wk High
127.22
127.22
52-wk Low
68.00
68.00
About
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) -... (more)
Overall
| Beta: | 0.41 |
| Market Cap(Mil.): | £705.16 |
| Shares Outstanding(Mil.): | 679.34 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| VEC.L | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 30.95 | 32.75 |
| EPS (TTM): | -- | -- | -- |
| ROI: | -- | 14.84 | 14.38 |
| ROE: | -- | 16.34 | 16.07 |
BRIEF-Sosei Says Does Not Intend To Make An Offer For Vectura
* CONFIRMS THAT IT DOES NOT INTEND TO MAKE AN OFFER FOR VECTURA
BRIEF-Vectura Says CFO Decided To Leave Group
* CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR ANDREW DERODRA HAS DECIDED TO LEAVE GROUP
Vectura posts wider 2017 loss, revenue rise
British drugmaker Vectura reported a worse-than-expected pretax loss for the full year on Wednesday, dragged by lower royalties and higher costs related to the SkyePharma deal.
CORRECTED-UPDATE 1-UK's Vectura posts wider 2017 loss, revenue rise
March 21 British drugmaker Vectura reported a worse-than-expected pretax loss for the full year on Wednesday, dragged by lower royalties and higher costs related to the SkyePharma deal.
BRIEF-Vectura Group Posts FY Reported Revenue Of 148.0 Mln Pounds
* FULL YEAR REPORTED REVENUE OF £148.0 MILLION, IN LINE WITH BOARD EXPECTATIONS (REPORTED 9M 2016: £126.5 MILLION)
BRIEF-Vectura Group Anticipates FY 2017 Revenue In Line With Board's Expectations
* FULL YEAR 2017 REVENUE ANTICIPATED TO BE IN LINE WITH BOARD'S EXPECTATIONS
Earnings vs. 
Estimates
- Should You Ditch GlaxoSmithKline plc And Buy Vectura Group PLC And SkyePharma PLC?
- Are Vectura Group PLC, AstraZeneca plc And Lookers PLC 'Screaming Buys'?
- Are Vectura Group PLC And Circassia Pharmaceuticals PLC Better Buys Than GlaxoSmithKline plc?
- Why Vectura Group PLC Could Be The Perfect Partner For AstraZeneca plc In Your Portfolio
- Profit From The Biotech Boom With Vectura Group PLC, Hikma Pharmaceuticals Plc And Indivior PLC